These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 1245763)

  • 1. Attenuated influenza virus in normal adults: role of pulmonary function studies in vaccine trials.
    Hall WH; Douglas RG; Zaky DA; Hyde RW; Richman D; Murphy BR
    J Infect Dis; 1976 Feb; 133(2):145-52. PubMed ID: 1245763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of live influenza virus vaccine in patients with chronic bronchitis. Report to Medical Research Council's Committee on Influenza and Other Respiratory Virus Vaccines. Advisory Group on pulmonary function tests in relation to live influenza virus vaccines.
    Br J Dis Chest; 1980 Apr; 74(2):121-7. PubMed ID: 7426351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of respiratory function in volunteers given live influenza virus vaccine.
    Nicholson KG; Lawford CV; Tyrrell DA
    Dev Biol Stand; 1977 Jun 1-3; 39():129-34. PubMed ID: 604095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
    Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secretory immune response after nasal vaccination with live attenuated influenza viruses.
    Crifö S; Vella S; Filiaci F; Resta S; Rocchi G
    Rhinology; 1980 Jun; 18(2):87-92. PubMed ID: 7403787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong/68-ts-1(E) (H3N2) and influenza A/Udorn/72-ts-1(E) (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen.
    Kim HW; Arrobio JO; Brandt CD; Parrott RH; Murphy BR; Richman DD; Chanock RM
    Pediatr Res; 1976 Apr; 10(4):238-42. PubMed ID: 1272630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trials of live attenuated influenza virus vaccine in patients with chronic obstructive airways disease. (MRC Advisory Group on Pulmonary Function Tests in relation to live influenza vaccines).
    Br J Dis Chest; 1984 Jul; 78(3):236-47. PubMed ID: 6378239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental studies on influenza A2 virus infection after peroral inoculation.
    Sidorova LA; Alekseyeva AK
    Acta Virol; 1973 Jul; 17(4):293-7. PubMed ID: 4148208
    [No Abstract]   [Full Text] [Related]  

  • 10. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin.
    Stech J; Garn H; Wegmann M; Wagner R; Klenk HD
    Nat Med; 2005 Jun; 11(6):683-9. PubMed ID: 15924146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E-rosette forming cells and humoral antibody titres in humans after vaccination with three different inactivated influenza virus vaccines A/USSR/92/77 (H1N1).
    Schmidt S; Süss J; Oehring H; Schmidt J
    Acta Virol; 1982 Dec; 26(6):466-73. PubMed ID: 6132540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain.
    Parks CL; Latham T; Cahill A; O'neill RE; Passarotti CJ; Buonagurio DA; Bechert TM; D'Arco GA; Neumann G; Destefano J; Arendt HE; Obregon J; Shutyak L; Hamm S; Sidhu MS; Zamb TJ; Udem SA
    Virology; 2007 Oct; 367(2):275-87. PubMed ID: 17599381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of a live attenuated influenza B virus vaccine candidate.
    Seo SU; Byun YH; Lee EY; Jung EJ; Jang YH; Kim HA; Ha SH; Lee KH; Seong BL
    Vaccine; 2008 Feb; 26(7):874-81. PubMed ID: 18207290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing.
    Noble S; McLain L; Dimmock NJ
    Vaccine; 2004 Aug; 22(23-24):3018-25. PubMed ID: 15297051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets.
    Huber VC; McCullers JA
    J Infect Dis; 2006 Mar; 193(5):677-84. PubMed ID: 16453263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.
    Horimoto T; Takada A; Iwatsuki-Horimoto K; Kawaoka Y
    Vaccine; 2004 Jun; 22(17-18):2244-7. PubMed ID: 15149783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
    Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
    J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a high-throughput Alamar blue assay for the determination of influenza virus infectious dose, serum antivirus neutralization titer and virus ca/ts phenotype.
    Mo C; Yamagata R; Pan A; Reddy J; Hazari N; Duke G
    J Virol Methods; 2008 Jun; 150(1-2):63-9. PubMed ID: 18423899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.